18:55:20

The Company’s Board of Directors resolved to inject capital into the 100% owned subsidiary, Diamond Biofund Ⅱ Inc.

1. Name and nature of the underlying assets (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield, etc.):Common shares of Diamond Biofund Ⅰ Inc.
2. Date of occurrence of the event:2023/12/22
3. Amount, unit price, and total monetary amount of the transaction:
   (1)An initial investment of NT$1 million was made for incorporation in November, 2023. It is planned for an additional capital injection of NT$999 million by the end of 2023, and an additional NT$1 billion in the first quarter of 2024, which could be conducted once or in different batches.
   (2)Amount and unit price: 200,000 thousand shares, par value at NT$10 per share
   (3)Total monetary amount of the transaction: NT$2 billion
4. Trading counterparty and its relationship with the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed):100% owned subsidiary
5. Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary amount of transfer:100% owned subsidiary
6. Where an owner of the underlying assets within the past five years has been a related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship with the Company at the time of the transaction: NA
7. Matters related to the current disposal of creditors’ rights (including types of collaterals of the disposed creditor’s rights; if creditor’s rights over a related party, announcement shall be made of the name of the related party and the book amount of the creditor’s rights, currently being disposed of, over such related party): NA
8. Profit or loss from the disposal (not applicable in cases of acquisition of securities) (those with deferral should provide a table explaining recognition):NA
9. Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important terms and conditions:NA
10. The manner of deciding on this transaction (such as invitation to tender, price comparison, or price negotiation), the reference basis for the decision on price, and the decision-making unit:
    (1)The transaction price is based on the par value per share of Diamond Biofund Ⅰ Inc.
    (2)The transaction is resolved by the Company’s Board of Directors.
11. Net worth per share of the Company’s underlying securities acquired or disposed of: NA
12. Cumulative no.of shares held (including the current transaction), their monetary amount, shareholding percentage, and status of any restriction of rights (e.g., pledges), as of the present moment:
    (1)Cumulative no. of shares held: 200,000 thousand shares
    (2)Cumulative monetary amount: NT$2 billion
    (3)Shareholding percentage: 100%
    (4)Restriction of rights: None
13. Current ratio of securities investment (including the current trade, as listed in article 3 of Regulations Governing the Acquisition and Disposal of Assets by Public Companies) to the total assets and equity attributable to owners of the parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as of the present:
    (1)Current ratio to the total assets: 15.73%
    (2)Current ratio to the equity attributable to owners of the parent: 15.80%
    (3)Working capital: NT$11,877,636 thousand
14. Broker and broker’s fee: NA
15. Concrete purpose or use of the acquisition or disposal:Operational needs
16. Any dissenting opinions of directors to the present transaction:None
17. Whether the counterparty of the current transaction is a related party:Yes
18. Date of the board of directors resolution:2023/12/22
19. Date of ratification by supervisors or approval bythe Audit Committee:2023/12/22
20. Whether the CPA issued an unreasonable opinion regarding the current transaction: NA
21. Name of the CPA firm: NA
22. Name of the CPA:NA
23. Practice certificate number of the CPA:NA
24. Whether the transaction involved in change of business model: No
25. Details on change of business model: NA
26. Details on transactions with the counterparty for the past year and the expected coming year: NA 
27. Source of funds:NA
28. Any other matters that need to be specified: None